OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
Ildiko Lingvay, John Deanfield, Steven E. Kahn, et al.
Diabetes Care (2024) Vol. 47, Iss. 8, pp. 1360-1369
Open Access | Times Cited: 20
Ildiko Lingvay, John Deanfield, Steven E. Kahn, et al.
Diabetes Care (2024) Vol. 47, Iss. 8, pp. 1360-1369
Open Access | Times Cited: 20
Showing 20 citing articles:
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Clinical Update in Heart Failure with Preserved Ejection Fraction
Chayakrit Krittanawong, William Britt, Affan Rizwan, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 5, pp. 461-484
Closed Access | Times Cited: 5
Chayakrit Krittanawong, William Britt, Affan Rizwan, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 5, pp. 461-484
Closed Access | Times Cited: 5
Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis
Deep Dutta, Radhika Jindal, Nishant Raizada, et al.
Indian Journal of Endocrinology and Metabolism (2025) Vol. 29, Iss. 1, pp. 4-12
Open Access
Deep Dutta, Radhika Jindal, Nishant Raizada, et al.
Indian Journal of Endocrinology and Metabolism (2025) Vol. 29, Iss. 1, pp. 4-12
Open Access
The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review
Stanislaus Ivanovich Krishnanda, Marie Christabelle, Oliver Emmanuel Yausep, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2239-2239
Open Access
Stanislaus Ivanovich Krishnanda, Marie Christabelle, Oliver Emmanuel Yausep, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2239-2239
Open Access
The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes
Christopher Lübker, Jigish Bhavsar, Ruben Vale, et al.
Advances in Therapy (2025)
Open Access
Christopher Lübker, Jigish Bhavsar, Ruben Vale, et al.
Advances in Therapy (2025)
Open Access
Adipositas und Diabetes
Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, et al.
Diabetes aktuell (2025) Vol. 23, Iss. 02, pp. 59-68
Closed Access
Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, et al.
Diabetes aktuell (2025) Vol. 23, Iss. 02, pp. 59-68
Closed Access
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
The cardiodiabetologist: not just a question of blood glucose levels
Francesca Muscente, Raffaele De Caterina
European Heart Journal Supplements (2025) Vol. 27, Iss. Supplement_3, pp. iii89-iii92
Open Access
Francesca Muscente, Raffaele De Caterina
European Heart Journal Supplements (2025) Vol. 27, Iss. Supplement_3, pp. iii89-iii92
Open Access
Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database
Jianxing Zhou, Wei Huang, Y. Xie, et al.
Endocrine (2024)
Closed Access | Times Cited: 3
Jianxing Zhou, Wei Huang, Y. Xie, et al.
Endocrine (2024)
Closed Access | Times Cited: 3
SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes
Grzegorz Gajos
Cardiology Journal (2024) Vol. 31, Iss. 5, pp. 782-783
Open Access | Times Cited: 2
Grzegorz Gajos
Cardiology Journal (2024) Vol. 31, Iss. 5, pp. 782-783
Open Access | Times Cited: 2
Lipid lowering effects of incretin-based therapies, relevant for cardiovascular benefit?
Teba Alnima, Mark M. Smits, Nordin M.J. Hanssen
Current Opinion in Lipidology (2024) Vol. 35, Iss. 6, pp. 259-267
Closed Access | Times Cited: 1
Teba Alnima, Mark M. Smits, Nordin M.J. Hanssen
Current Opinion in Lipidology (2024) Vol. 35, Iss. 6, pp. 259-267
Closed Access | Times Cited: 1
Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024?
Zahra Ismail, Maryam Aboughdir, Bea Duric, et al.
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 1
Zahra Ismail, Maryam Aboughdir, Bea Duric, et al.
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 1
Adipositas und Diabetes
Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, et al.
Diabetologie und Stoffwechsel (2024) Vol. 19, Iss. S 02, pp. S270-S278
Closed Access | Times Cited: 1
Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, et al.
Diabetologie und Stoffwechsel (2024) Vol. 19, Iss. S 02, pp. S270-S278
Closed Access | Times Cited: 1
Deciphering the Effects of Semaglutide Across the Glycemic Spectrum
Shivani Misra
Diabetes Care (2024)
Open Access
Shivani Misra
Diabetes Care (2024)
Open Access
Dysglycaemia in cardiovascular disease: what's the best glycaemic risk predictor?
Stefano Del Prato
The Lancet Diabetes & Endocrinology (2024)
Closed Access
Stefano Del Prato
The Lancet Diabetes & Endocrinology (2024)
Closed Access
Kardiovaskuläre Risikoreduktion durch Semaglutid unabhängig von HbA1c
Diabetologie und Stoffwechsel (2024) Vol. 19, Iss. 05, pp. 308-310
Closed Access
Diabetologie und Stoffwechsel (2024) Vol. 19, Iss. 05, pp. 308-310
Closed Access
A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure
Ushna Gul, Thazin Nwe Aung, Mehwish Martin, et al.
Cureus (2024)
Open Access
Ushna Gul, Thazin Nwe Aung, Mehwish Martin, et al.
Cureus (2024)
Open Access
Semaglutide and major adverse cardiovascular events in patients with and without DM: a systematic review and meta-analysis
Yànhuá Lǐ, Chunmei Lv, Lianlian Cao, et al.
Research Square (Research Square) (2024)
Closed Access
Yànhuá Lǐ, Chunmei Lv, Lianlian Cao, et al.
Research Square (Research Square) (2024)
Closed Access
Beneficial cardio‐metabolic effects of semaglutide in individuals living with overweight/obesity without type 2 diabetes. Additional analysis of the SELECT trial
Iskandar Idris
Diabetes Obesity and Metabolism Now (2024) Vol. 2, Iss. 7
Closed Access
Iskandar Idris
Diabetes Obesity and Metabolism Now (2024) Vol. 2, Iss. 7
Closed Access
Semaglutide effects on cardiovascular outcomes in individuals with overweight or obesity who do not have diabetes: a systematic review
Anna Klasa, Aleksandra Sobaś, Kamil Biedka, et al.
MEDICAL SCIENCE PULSE (2024)
Open Access
Anna Klasa, Aleksandra Sobaś, Kamil Biedka, et al.
MEDICAL SCIENCE PULSE (2024)
Open Access
